Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...